Average Insider

Where insiders trade, we follow

$KAPA
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, California.
Healthcare
Sector
Biotechnology
Industry
John S. Yu
CEO
1
Employees
$0.57
Current Price
$18.10M
Market Cap
52W Low$0.40
Current$0.579.9% above low, 90.1% below high
52W High$2.11

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00---
Sells00--
2 weeksBuys00---
Sells00--
1 monthBuys00---
Sells00--
2 monthsBuys00---
Sells00--
3 monthsBuys00---
Sells00--
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
No insider transactions found

Upcoming Earnings

Scheduled earnings reports
Apr 21, 2026
EPS
Estimated-$0.12
ActualN/A
Revenue
EstimatedN/A
ActualN/A

Past Earnings

Historical earnings results
No past earnings data available
Version: v26.3.23